Ovid Therapeutics Inc(OVID) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.25 | Insider Own | 7.38% | Shs Outstand | 184.8M | Perf Week | 17.59% |
| Market Cap | 0.50B | Forward P/E | - | EPS next Y | -6.96% | Insider Trans | - | Shs Float | 180.9M | Perf Month | 4.53% |
| Enterprise Value | 0.39B | PEG | - | EPS next Q | -0.08 | Inst Own | 79.48% | Short Float | 9.99% | Perf Quarter | 9.01% |
| Income | -0.03B | P/S | 313.96 | EPS this Y | -56.74% | Inst Trans | 27.43% | Short Ratio | 10.82 | Perf Half Y | -8.96% |
| Sales | 0.00B | P/B | 2.24 | EPS next 5Y | -20.07% | ROA | -22.3% | Short Interest | 18.07M | Perf YTD | 55.83% |
| Book/sh | 1.14 | P/C | 4.23 | EPS past 3/5Y | 32.53% 29.81% | ROE | -25.96% | 52W High | -18.2% ($3.11) | Perf Year | 85.4% |
| Cash/sh | 0.6 | P/FCF | - | Sales past 3/5Y | 68.99% -10.48% | ROIC | -15.6% | 52W Low | 115.25% ($1.18) | Perf 3Y | -27.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 52.86% | Gross Margin | 92.92% | Volatility(W/M) | 8.86% 7.82% | Perf 5Y | -25.29% |
| Dividend TTM | - | EV/Sales | 247.81 | Sales Y/Y TTM | -76.2% | Oper. Margin | -3686.67% | ATR (14) | 0.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.39 | EPS Q/Q | -15.33% | Profit Margin | -2178.84% | RSI (14) | 56.13 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.39 | Sales Q/Q | -88.31% | SMA20 | 9.09% ($2.33) | Beta | 0.25 | Target Price | $6.4 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/13 | SMA50 | 0.04% ($2.54) | Rel Volume | 1.88 | Prev Close | $2.56 |
| Employees | 23 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 30.43% 3325.23% | SMA200 | 7.49% ($2.36) | Avg Volume(3M) | 1.67M | Price | $2.54 |
| IPO | 2017/5/5 | Option/Short | Yes/Yes | Trades | 5727 | Volume | 3,145,568 | Change | -0.78% |
A U.S. clinical-stage biotech company developing small-molecule therapies for hard-to-treat neurological and central nervous system disorders. Its lead candidate targets drug-resistant epilepsy, and its broader pipeline focuses on neuromodulation approaches aimed at restoring the brain's excitatory–inhibitory balance, with a strategic emphasis on neurological and psychiatric conditions marked by significant unmet medical needs.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded more than usual. That is 188% of its average volume.
OVID has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -56.7% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $31,396. Peers typically go for $1,268.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -25.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 79.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #218 of 597 in the industry
Based on market cap of $496M.
ETRA#215 Electra Therapeutics Inc $508M PER - 
CBIO#216 Crescent Biopharma Inc $501M PER - 
DMAC#217 DiaMedica Therapeutics Inc $499M PER - OVID#218 Ovid Therapeutics Inc $496M PER - 
GYRE#219 Gyre Therapeutics Inc $483M PER - 
FAQ
What kind of company is OVID?
OVID belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OVID?
The market cap of OVID is approximately $496M, ranking 3,147 within its sector.
What is the 52-week high and low for OVID?
OVID has recorded a 52-week high of $3.11 and a low of $1.18.
